Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.

Drug metabolism and disposition: the biological fate of chemicals - 1 Oct 2025

Luo Shaman, Trudeau Julia, Ho Vikki, Richardson Harriet, Lazarus Philip

Abstract excerpt

Exemestane (EXE) is an aromatase inhibitor used for the treatment of estrogen receptor-positive breast cancer. The metabolism of EXE includes reduction to form 17-β-hydroxy-EXE (17β-DHE) and subsequent UGT2B17-mediated glucuronidation to form 17-β-hydroxy-EXE-17-O-β-D-glucuronide (17β-DHE-Gluc), and GSTA1-mediated glutathione conjugation of EXE and 17β-DHE and subsequent sequential metabolism by γ-glutamyl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstadienes
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GSTA1 gene

Share to Genotype

Share to Glucuronosyltransferase

Share to Glutathione Transferase

Share to Minor Histocompatibility Antigens

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 40972495
DOI: 10.1016/j.dmd.2025.100148
PMCID: PMC13340755

Genes

UGT2B17
GSTA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.PMID 40972495Read ↗

Influence of glutathione-S-transferase polymorphisms on the metabolism of the potent aromatase inhibitor, exemestaneSemantic proximity Read ↗

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.Semantic proximity Read ↗

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Semantic proximity Read ↗

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.Semantic proximity Read ↗

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.Semantic proximity Read ↗

Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.Semantic proximity Read ↗

Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.Semantic proximity Read ↗

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.Semantic proximity Read ↗

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Semantic proximity Read ↗

Differences in 4-hydroxyestradiol levels in leukocytes are related to CYP1A1(∗)2C, CYP1B1(∗)3 and COMT Val158Met allelic variants.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on the Sulfation of Dehydroepiandrosterone and 17-β Estradiol by Human Cytosolic Sulfotransferase SULT2B1aSemantic proximity Read ↗

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.